VERA Vera Therapeutics (VERA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001831828
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
131
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $368.0K priced
What the filings say about VERA
Insiders, 180 days
-$4.7M net sold
1 seller · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.2M
1 notice
Vera Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Vera Therapeutics, Inc. insiders sold a net $4.7M of stock across 221 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 80 earlier Form 4 trades (code P or S) here by this insider (80 sales), the last on Sep 2, 2026.
- The trade is 7.9% of the 235,244 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Fordyce Marshall sold about $684.5K of VERA under a 10b5-1 plan on Sep 15, 2026; 131 funds added in the latest 13F quarter.Context
- 79 earlier Form 4 trades (code P or S) here by this insider (79 sales), the last on Jul 7, 2026.
- The trade is 7.9% of the 235,244 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Fordyce Marshall sold about $649.6K of VERA under a 10b5-1 plan on Sep 2, 2026; 131 funds added in the latest 13F quarter.Context
- 75 earlier Form 4 trades (code P or S) here by this insider (75 sales), the last on Jun 23, 2026.
- The trade is 0.4% of the 280,494 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Fordyce Marshall sold about $40.8K of VERA on Jul 7, 2026; 131 funds added in the latest 13F quarter.Context
- 75 earlier Form 4 trades (code P or S) here by this insider (75 sales), the last on Jun 23, 2026.
- The trade is 13.1% of the 247,944 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Fordyce Marshall sold about $1.4M of VERA on Jul 7, 2026, the largest insider sale at the company since 2024; 131 funds added in the latest 13F quarter.Context
- 75 earlier Form 4 trades (code P or S) here by this insider (75 sales), the last on Jun 23, 2026.
- The trade is 4.4% of the 237,444 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Fordyce Marshall sold about $450.0K of VERA on Jul 7, 2026; 131 funds added in the latest 13F quarter.221 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.7M over 180 days
-$1.3M over 90 days
below 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
131 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
32.9% of the float short (float per yahoo 2026-10-26) · 7.8 days to cover · settled 2026-09-30
more than 98% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VERA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.3%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VERA: institutional holders (13F)
13F holdings, latest reported quarter
5,747,760 sh
$246.6M
5,723,888 sh
$245.6M
4,148,786 sh
$178.0M
4,000,000 sh
$171.6M
3,916,400 sh
$168.1M
Congress trades in VERA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VERA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MARSHALL FORDYCE
Filed 2026-09-02
$2.2M
MARSHALL FORDYCE
Filed 2026-06-23
$2.8M
VERA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$2.6M position · as of 2026-05-31
1.6%
AMG Frontier Small Cap Growth Fund
$1.4M position · as of 2026-07-31
1.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$113.7M position · as of 2026-06-30
1.1%
PROFUND VP BIOTECHNOLOGY
$502.8K position · as of 2026-06-30
1.0%
AMG GW&K Small Cap Growth Fund
$1.9M position · as of 2026-07-31
0.9%
DWS Small Cap Growth Fund
$2.4M position · as of 2026-06-30
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
3 active
2
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.7M sold by insiders over 180 days, 131 funds added last quarter, $2.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
VERA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM VERA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM VERA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$338.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VERA
| FY Dec 2025 | -$241.7M |
| FY Dec 2024 | -$135.7M |
| FY Dec 2023 | -$92.2M |
| FY Dec 2022 | -$67.7M |
| FY Dec 2021 | -$23.7M |
| Jun 2026 | -$100.3M |
| Mar 2026 | -$106.5M |
| Dec 2025 | -$70.1M |
| Sep 2025 | -$62.0M |
| Jun 2025 | -$55.0M |
| Mar 2025 | -$54.6M |
| Dec 2024 | -$39.8M |
| Sep 2024 | -$37.1M |
At each fiscal year end
Single quarter
Debt to equity
0.18x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity VERA
| FY Dec 2025 | 0.12x |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | 0.49x |
| FY Dec 2022 | 0.32x |
| FY Dec 2021 | 0.07x |
| Jun 2026 | 0.18x |
| Mar 2026 | 0.15x |
| Dec 2025 | 0.12x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.16x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-4.50x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt VERA
| FY Dec 2025 | -3.22x |
| FY Dec 2024 | -2.66x |
| FY Dec 2023 | -1.85x |
| FY Dec 2022 | -2.72x |
| FY Dec 2021 | -4.82x |
| Jun 2026 | -4.50x |
| Mar 2026 | -3.91x |
| Dec 2025 | -3.22x |
| Sep 2025 | -2.82x |
| Jun 2025 | -2.49x |
| Mar 2025 | -3.05x |
| Dec 2024 | -2.66x |
| Sep 2024 | -2.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-91.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VERA
| FY Dec 2025 | -50.7% |
| FY Dec 2024 | -44.8% |
| FY Dec 2023 | -107.5% |
| FY Dec 2022 | -121.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | -91.8% |
| Mar 2026 | -71.3% |
| Dec 2025 | -50.7% |
| Sep 2025 | -73.2% |
| Jun 2025 | -54.8% |
| Mar 2025 | -39.5% |
| Dec 2024 | -44.8% |
| Sep 2024 | -65.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-72.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VERA
| FY Dec 2025 | -43.1% |
| FY Dec 2024 | -36.6% |
| FY Dec 2023 | -62.5% |
| FY Dec 2022 | -82.8% |
| FY Dec 2021 | -47.2% |
| Jun 2026 | -72.3% |
| Mar 2026 | -59.9% |
| Dec 2025 | -43.1% |
| Sep 2025 | -56.9% |
| Jun 2025 | -44.7% |
| Mar 2025 | -34.1% |
| Dec 2024 | -36.6% |
| Sep 2024 | -49.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital VERA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-80.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VERA
| FY Dec 2025 | -48.1% |
| FY Dec 2024 | -42.7% |
| FY Dec 2023 | -78.8% |
| FY Dec 2022 | -100.0% |
| FY Dec 2021 | -53.7% |
| Jun 2026 | -80.8% |
| Mar 2026 | -65.8% |
| Dec 2025 | -48.1% |
| Sep 2025 | -66.1% |
| Jun 2025 | -51.1% |
| Mar 2025 | -38.9% |
| Dec 2024 | -42.7% |
| Sep 2024 | -58.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VERA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.2B
market value at close 2026-10-27 on 2026-07-29 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value VERA
| FY Dec 2025 | $3.0B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $687.6M |
| FY Dec 2022 | $516.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | $3.1B |
| Mar 2026 | $2.5B |
| Dec 2025 | $3.0B |
| Sep 2025 | $1.9B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.5B |
| Dec 2024 | $2.6B |
| Sep 2024 | $2.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-15.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield VERA
| FY Dec 2025 | -7.5% |
| FY Dec 2024 | -5.1% |
| FY Dec 2023 | -13.5% |
| FY Dec 2022 | -12.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | -11.0% |
| Mar 2026 | -11.4% |
| Dec 2025 | -7.5% |
| Sep 2025 | -11.4% |
| Jun 2025 | -12.4% |
| Mar 2025 | -10.3% |
| Dec 2024 | -5.1% |
| Sep 2024 | -5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VERA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M |
| EPS (diluted) | -4.66 | -2.75 | -2.25 | -3.35 |
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M |
| Cash | $354.7M | $92.6M | $45.7M | $43.5M |
| Long-term debt | $74.8M | $50.7M | $49.9M | $24.8M |
| Buybacks | $0 | $13.0K | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
VERA Stock Sonar score 5/7 axes
Find similar shapesCompareVERA ranks highest on institutional and government (78th percentile) and financial health (39th), and lowest on risk and compliance (2nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VERA filings, in plain words
Are Vera Therapeutics insiders buying or selling VERA?
In the 180 days to 2026-10-28, Vera Therapeutics insiders were net sellers, a net $4.7M across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of VERA?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $2.2M of stock; the latest, by MARSHALL FORDYCE, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, Vera Therapeutics insiders were net sellers of VERA, a net $4.7M across purchases and sales reported on Form 4 by 1 seller. 20% of the 10 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $2.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
